Maverick has been shown to detect only four copies pathogen molecule DNA per sample with over nine orders of magnitude in dynamic range.
Applications include near-patient diagnostics as well as food, agriculture and environment testing.
The firm has demonstrated the technology in detecting pathogen DNA and RNA strands such as Hepatitis B and C and E. coli.
Maverick is available now for evaluation through Anitoa's early access program (EAP) and commercial release is planned for Q3 2018.
Technology includes a proprietary low-light sensitive, complementary metal-oxide-semiconductor (CMOS) 4-channel fluorescence optics system that allows fast and multiplexed DNA detection without field calibration.
This replaces traditional photon-multiplier tube (PMT) and CCD-based optical sub-systems.
Maverick has a cloud-based software connected to the Internet and enables cloud data storage and retrieval.
Dr Zhimin Ding, CEO of Anitoa Systems, said the portable qPCR device has performance that rivals lab-based systems.
"We strive to make our molecular testing systems rugged, accessible, and with battery operation and power-loss protection capability to facilitate their effective use in low resource settings."